This post was originally published on this site
https://i-invdn-com.investing.com/trkd-images/LYNXMPEHA411T_L.jpg
The FDA has now authorized 11 batches of the vaccine manufactured at the facility.
In April, U.S. authorities halted production after ingredients from AstraZeneca (NASDAQ:AZN)’s COVID-19 vaccine, also being produced at the plant at the time, contaminated a batch of J&J’s vaccine.
Today’s authorization was based on a thorough review of facility records and quality testing by the manufacturer, and considering the current COVID-19 public health emergency, the health agency said in a statement.
An estimated 30 million to 50 million doses of Johnson & Johnson’s COVID-19 vaccine made early this year have been sitting idle in the Baltimore plant for weeks awaiting a green light from U.S. regulators to ship, two sources familiar with the matter told Reuters late last month.
